Review
Oncology
Randy S. D'Amico, Manish K. Aghi, Michael A. Vogelbaum, Jeffrey N. Bruce
Summary: Convection-enhanced delivery (CED) is a method of targeted, local drug delivery to the central nervous system that shows promise for treating glioblastoma (GBM), although the long-term efficacy of the agents studied remains difficult to assess at present.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
Jasleen Kaur, Guangliang Ding, Li Zhang, Yong Lu, Hao Luo, Lian Li, Edward Boyd, Qingjiang Li, Min Wei, Zhenggang Zhang, Michael Chopp, Quan Jiang
Summary: The study demonstrated the impact of GBM on the glymphatic response in the rat brain. Reduced glymphatic waste clearance may lead to the accumulation of toxic waste solutes.
Review
Materials Science, Biomaterials
Zijun Wu, Lixiong Dai, Ke Tang, Yiqi Ma, Bin Song, Yanrong Zhang, Jinxing Li, Su Lui, Qiyong Gong, Min Wu
Summary: GBM is the most aggressive malignant brain tumor with limited treatment options. Current clinical contrast agents have limitations in accurately distinguishing GBM from surrounding tissues, leading to the urgent need for new GBM-specific contrast agents. Advances in nanotechnology have provided alternative options for GBM-targeting contrast agents.
REGENERATIVE BIOMATERIALS
(2021)
Article
Chemistry, Multidisciplinary
Meng Yang, Bingyi Wang, Ying Yin, Xiaoyue Ma, Lin Tang, Yu Zhang, Qin Fan, Tieying Yin, Yazhou Wang
Summary: A self-assembled dual-targeted hybrid micelle (DT-GM1) was developed as a nanocarrier to deliver the chemotherapeutic agent doxorubicin (DOX). The DT-GM1/DOX was shown to cross the blood-brain barrier and target the tumor microenvironment enriched with immunosuppressed M2-like tumor-associated macrophages (M2 TAMs) and glioblastoma stem cells (GSCs), resulting in increased intracellular drug accumulation and reshaping of the immune microenvironment. This nanocarrier provides a promising new strategy for glioblastoma (GBM) treatment.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Biochemistry & Molecular Biology
Elza N. Mathew, Bethany C. Berry, Hong Wei Yang, Rona S. Carroll, Mark D. Johnson
Summary: This review addresses the impact of tumor invasion, molecular and cellular heterogeneity, and the blood-brain barrier on drug delivery and distribution in glioblastoma, and introduces potential therapeutic delivery options.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Nanoscience & Nanotechnology
Shi-Hui Liu, Qing-Zhen Wang, Tao Liu, Ru Bai, Man-Man Ma, Qiao-Lin Liu, Hui-Ge Zhou, Jing Liu, Mei Wang
Summary: This study presents a promising strategy to improve the selectivity and antitumor efficacy of glioblastoma drugs by using protein nanoparticles as carriers.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Chiara Bastiancich, Samantha Fernandez, Florian Correard, Anthony Novell, Benoit Larrat, Benjamin Guillet, Marie-Anne Esteve
Summary: In this study, nuclear imaging was used to quantify the impact of focused ultrasound (FUS) on blood-brain barrier (BBB) opening and tumor growth. The results showed that FUS did not influence tumor growth, and molecular imaging can be used to evaluate the time frame and efficacy of systemic treatment combined with transient BBB opening.
Review
Pharmacology & Pharmacy
Chiara Bastiancich, Alessio Malfanti, Veronique Preat, Ruman Rahman
Summary: Local drug delivery is an effective way to treat GBM, allowing for immediate post-surgery treatment and bypassing the blood-brain barrier to reduce systemic side effects. Rational design of biomaterials and drug delivery systems is crucial for preventing tumor recurrence.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Article
Nanoscience & Nanotechnology
Jamie M. Gleason, Sarah H. Klass, Paul Huang, Tomoko Ozawa, Raquel A. Santos, Miko M. Fogarty, David R. Raleigh, Mitchel S. Berger, Matthew B. Francis
Summary: Lipid and micelle-based nanocarriers have been studied for delivering anticancer drugs to improve their accumulation and uptake in tumor tissue. In this study, a protein-based micelle nanocarrier called IDP-2Yx2A was developed to encapsulate a highly potent but water-insoluble cancer drug, SN38, for delivery into glioblastoma multiforme (GBM) tumors. The results showed promising in vivo efficacy with slowed tumor growth and increased median survival times.
ACS APPLIED BIO MATERIALS
(2022)
Article
Nanoscience & Nanotechnology
Sauradip Chaudhuri, Martha J. Fowler, Cassandra Baker, Sylwia A. Stopka, Michael S. Regan, Lindsey Sablatura, Colton W. Broughton, Brandon E. Knight, Sarah E. Stabenfeldt, Nathalie Y. R. Agar, Rachael W. Sirianni
Summary: This research introduces a novel nanocarrier platform for encapsulating HDACi, improving drug delivery efficiency, and providing insights into the structural requirements for effective drug loading and self-assembly of nanoparticles. The optimized CDN nanoparticles show promising results in slowing tumor growth and increasing exposure of tumors to drugs, indicating a step forward in HDACi therapy for better disease treatment.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Chemistry, Multidisciplinary
Claudia Martins, Marco Araujo, Alessio Malfanti, Catarina Pacheco, Stuart J. J. Smith, Bernard Ucakar, Ruman Rahman, Jonathan W. W. Aylott, Veronique Preat, Bruno Sarmento
Summary: Report the development of hypothesis-driven stimuli-responsive nanoparticles (NPs) for glioblastoma (GBM) therapy. These NPs have multifunctional features that overcome the insufficient blood-brain barrier (BBB) trafficking and lack of GBM targeting, two major challenges in anti-GBM treatments. In preclinical studies, the stimuli-responsive NPs effectively targeted GBM cells, enhanced cell uptake, increased cytotoxicity, improved BBB permeability, and demonstrated antitumor efficacy in GBM models.
Article
Chemistry, Multidisciplinary
Huanhuan Sun, Wenjie Ma, Shuangdi Duan, Jin Huang, Ruichen Jia, Hong Cheng, Biao Chen, Xiaoxiao He, Kemin Wang
Summary: The development of stimuli-responsive nanoplatforms for cancer theranostics is valuable. A nanocluster-bomb activated by endogenous legumain is created for enhanced tumor imaging and controlled gene/drug release. The disaggregation of the nanobomb triggered by legumain improves imaging contrast and enables efficient gene/chemo combination therapy.
Article
Medicine, Research & Experimental
Shixue Yang, Jixing Zhao, Xiaoteng Cui, Qi Zhan, Kaikai Yi, Qixue Wang, Menglin Xiao, Yanli Tan, Biao Hong, Chuan Fang, Chunsheng Kang
Summary: The study demonstrates that targeted inhibitors can effectively disrupt energy metabolism in GBM and inhibit tumor proliferation.
Article
Medicine, Research & Experimental
Constantine J. Georgiou, Zhongli Cai, Noor Alsaden, Hyungjun Cho, Minou Behboudi, Mitchell A. Winnik, James T. Rutka, Raymond M. Reilly
Summary: In this study, convection-enhanced delivery (CED) of 23 +/- 3 nm gold nanoparticles (AuNPs) labeled with the beta-particle-emitting radionuclide 177Lu (177Lu-AuNPs) was found to be highly effective for treating orthotopic U251-Luc human glioblastoma multiforme (GBM) tumors in NRG mice. The cytotoxicity of 177Lu-AuNPs on U251-Luc cells was confirmed through in vitro experiments, while in vivo studies showed that the tumors treated with 177Lu-AuNPs exhibited growth arrest and improved long-term survival compared to control mice. Overall, this study highlights the potential of CED using 177Lu-AuNPs as a promising treatment for GBM patients. Rating: 8/10
MOLECULAR PHARMACEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Bilal Javed, Xinyi Zhao, Daxiang Cui, James Curtin, Furong Tian
Summary: The study synthesized Lignin-g-p (NIPAM-co-DMAEMA) gold nanogel loaded with curcumin and piperine to treat GBM, which exhibited enhanced anticancer properties, improved drug toxicity and release, and induced apoptosis through endocytic pathways. The experimental evidence suggests that the combinatorial curcumin-piperine gold nanogels have the potential to overcome the limitations of conventional chemotherapeutic treatments for glioma cells.
Review
Immunology
Ronit Mazor, Ira Pastan
FRONTIERS IN IMMUNOLOGY
(2020)
Review
Oncology
Kelly M. Hotchkiss, John H. Sampson
Summary: GBM is difficult to eradicate with immunotherapy and chemotherapy, and different doses and timing of chemotherapy may affect tumor eradication efficacy.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjorn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Federico Rotolo, Emmanuel Mitry, Ira Pastan, Francis Giles
Summary: Moxetumomab pasudotox demonstrated a high rate of durable responses and minimal residual disease negativity in patients with relapsed/refractory hairy cell leukemia, with a manageable safety profile.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Urology & Nephrology
Jun Zou, Jaewon Yang, Xiaoye Zhu, Jianyong Zhong, Ahmed Elshaer, Taiji Matsusaka, Ira Pastan, Volker H. Haase, Hai-Chun Yang, Agnes B. Fogo
Summary: The study found that stabilizing hypoxia-inducible factor-alpha (HIF-alpha) can ameliorate tubulointerstitial injury and reduce its impact on subsequent glomerular injury. Restoring HIFs may blunt the adverse crosstalk between tubular injury and glomerular injury.
KIDNEY INTERNATIONAL
(2021)
Letter
Oncology
Ilana R. Yurkiewicz, Steve Coutre, Herve Ghesquieres, Ira Pastan, Robert J. Kreitman
LEUKEMIA & LYMPHOMA
(2021)
Article
Multidisciplinary Sciences
Takahiro Nishio, Yukinori Koyama, Xiao Liu, Sara B. Rosenthal, Gen Yamamoto, Hiroaki Fuji, Jacopo Baglieri, Na Li, Laura N. Brenner, Keiko Iwaisako, Kojiro Taura, James S. Hagood, Nicholas F. LaRusso, Tapan K. Bera, Ira Pastan, David A. Brenner, Tatiana Kisseleva
Summary: The role of Mesothelin and Thy1 in fibroblast activation was investigated, with Mesothelin-deficient mice being protected from fibrosis while Thy1-deficient mice were more susceptible. Targeting of human MSLN* aPFs with anti-MSLN immunotoxins reduced collagen deposition in injured mice, suggesting antimesothelin therapy as a potential strategy for parenchymal organ fibrosis treatment.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Editorial Material
Biochemistry & Molecular Biology
Robert J. Kreitman, Ira Pastan
Article
Oncology
Sakshi Tomar, Jingli Zhang, Manakamana Khanal, Jessica Hong, Abhilash Venugopalan, Qun Jiang, Manjistha Sengupta, Markku Miettinen, Nan Li, Ira Pastan, Mitchell Ho, Raffit Hassan
Summary: This study demonstrates that CAR T cells targeting mesothelin epitopes close to the cell membrane, such as hYP218, are highly effective against mesothelin-positive tumors, with increased persistence and tumor infiltration.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Oncology
Jiajia Pan, Nan Li, Alex Renn, Hu Zhu, Lu Chen, Min Shen, Matthew D. Hall, Min Qian, Ira Pastan, Mitchell Ho
Summary: The cell surface proteoglycan GPC1 is overexpressed in multiple types of human cancers, including pancreatic cancer. In this study, researchers constructed GPC1-targeted immunotoxins and found that these immunotoxins can inhibit pancreatic tumor growth. Combining the immunotoxin with irinotecan further enhanced its efficacy.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Multidisciplinary Sciences
Xiufen Liu, Masanori Onda, Nathan Watson, Raffit Hassan, Mitchell Ho, Tapan K. Bera, Junxia Wei, Anirban Chakraborty, Richard Beers, Qi Zhou, Asif Shajahan, Parastoo Azadi, Jingyu Zhan, Di Xia, Ira Pastan
Summary: Researchers have identified a monoclonal antibody that inhibits the shedding of the protein MSLN, which is highly expressed by cancer cells. The antibody binds to the protease-sensitive region of MSLN and CAR T cells produced with this antibody show superior antitumor activity.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Multidisciplinary Sciences
Yaoying Wu, Hanning Wen, Zachary J. Bernstein, Kelly M. Hainline, Tykia S. Blakney, Kendra L. Congdon, David J. Snyder, John H. Sampson, Luis Sanchez-Perez, Joel H. Collier
Summary: The study demonstrates the potential clinical benefit of vaccine-induced antibody responses for tumor treatments when combined with simultaneous CD8(+) and CD4(+) responses, using a nanofiber vaccine design approach. Additionally, the study highlights the importance of supramolecular nanomaterials in developing multiepitope cancer vaccines.
Article
Oncology
Guillaume Joe Pegna, Min-Jung Lee, Cody J. Peer, Mehwish Ahmad, David J. Venzon, Yunkai Yu, Akira Yuno, Seth M. Steinberg, Liang Cao, William D. Figg, Renee N. Donahue, Raffit Hassan, Ira Pastan, Jane B. Trepel, Christine Alewine
Summary: The clinical trial of LMB-100 demonstrated some clinical efficacy but also revealed the potential intolerable side effect of capillary leak syndrome (CLS) when combined with nab-paclitaxel. Furthermore, LMB-100 treatment was found to cause systemic immune activation and associated inflammatory and immune changes.
Article
Physiology
Kazuyoshi Yamamoto, Masahiro Okabe, Keiko Tanaka, Takashi Yokoo, Ira Pastan, Toshikazu Araoka, Kenji Osafune, Tomohiro Udagawa, Masahiro Koizumi, Taiji Matsusaka
Summary: This study clarifies why morphologically definitive apoptosis is rarely observed in podocytes in vivo. When caspase-3 is activated in podocytes, these cells are immediately detached from the glomerulus and lost in the urine before DNA fragmentation occurs. Detachment is facilitated by glomerular filtration. This phenomenon explains why podocytes in vivo rarely show TUNEL staining and never apoptotic bodies.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
(2022)
Article
Multidisciplinary Sciences
Guannan Wang, Alok Kumar, Wanjun Ding, Preethi Korangath, Tapan Bera, Junxia Wei, Priya Pai, Kathleen Gabrielson, Ira Pastan, Saraswati Sukumar
Summary: The study demonstrated potent antitumor effects of intraductal injection of HB21(Fv)-PE40 on breast cancer, providing a strong preclinical foundation for conducting feasibility and safety trials in breast cancer patients.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Physiology
Masahiro Okabe, Kazuyoshi Yamamoto, Yoichi Miyazaki, Masaru Motojima, Masato Ohtsuka, Ira Pastan, Takashi Yokoo, Taiji Matsusaka
Summary: The study revealed that damaged podocytes in a mosaic mouse model can lead to secondary injury in other podocytes, and treatment with angiotensin II receptor blocker significantly ameliorated the secondary podocyte injury. Understanding the molecular mechanism of secondary podocyte injury is crucial for treating progressive kidney diseases, and this model serves as a powerful tool for studying indirect podocyte damage.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
(2021)
